Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results provided direct evidence for a novel, PPARα-mediated mechanism responsible for the beneficial effects of RSV on hepatic steatosis.
|
31173696 |
2020 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
PPARα contributes to the CYP2A5 protective effects on fatty liver but it opposes to the protective effects on obesity.
|
29568101 |
2019 |
Fatty Liver
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Pparα promoter.
|
30404040 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated lipolysis in adipose tissue by doxorubicin via PPARα activation associated with hepatic steatosis and insulin resistance.
|
30452912 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation.
|
31589122 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
During the development of hepatic steatosis (8-16 weeks), PPARα was activated as indicated by its target genes as well as the elevated peroxisomal acyl-CoA oxidase activity.
|
30120929 |
2018 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aged and Zmpste24-deficient livers share several features, including nuclear lamina abnormalities, increased Foxa2 binding, de-repression of PPAR- and LXR-dependent gene expression, and fatty liver.
|
29484800 |
2018 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IRD induced liver steatosis and oxidative stress (higher levels of protein oxidation and lipid peroxidation with glutathione depletion), mitochondrial dysfunction (decreased citrate synthase and complex I and II activities) and loss of polyunsaturated fatty acids (PUFAs), with a drastic enhancement in the sterol regulatory element-binding protein-1c (SREBP-1c)/peroxisome proliferator-activated receptor-α (PPAR-α) ratio upregulating the expression of lipogenic enzymes (acetyl-CoA carboxylase, fatty acid (FA) synthase and stearoyl desaturase 2) and downregulating those involved in FA oxidation (carnitine palmitoyl transferase and acyl-CoA oxidase) over values in the CD group.
|
30153476 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ameliorative effect of Sedum sarmentosum Bunge extract on Tilapia fatty liver via the PPAR and P53 signaling pathway.
|
29855491 |
2018 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed that the overexpression of PIK3R3 promoted hepatic fatty acid oxidation via PIK3R3-induced expression of PPARα, thus improving the fatty liver phenotype in high-fat diet (HFD)-induced mice.
|
29350678 |
2018 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, MG clearly alleviated serum TG and total cholesterol release; upregulated AKT, AMPK, and PPARα expression; suppressed SREBP-1c generation; and alleviated hepatic steatosis and dyslipidemia in Ty-induced hyperlipidemia mice.
|
29467759 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Nuciferine improved lipid profile and attenuated hepatic steatosis in HFD/STZ-induced diabetic mice by activating the PPARα/PGC1α pathway.
|
30129056 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, fatty liver in PUFA deficiency is attributable to suppression of the FA-degrading system probably from decreased PPARα adaptive responsiveness, and PUFA may be an essential factor for PPARα functioning.
|
28724855 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Supplementation with Docosahexaenoic Acid and Extra Virgin Olive Oil Prevents Liver Steatosis Induced by a High-Fat Diet in Mice through PPAR-α and Nrf2 Upregulation with Concomitant SREBP-1c and NF-kB Downregulation.
|
28940752 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
|
28545035 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD.
|
29042644 |
2017 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hepatic miR-141 and miR-200c RNA levels were highly induced in human patients with NASH fatty liver and in WT MCD mice. miR-141/200c-/- MCD mice had reduced liver weights and triglyceride (TG) levels, which was associated with increased microsomal TG transfer protein (MTTP) and PPARα but reduced SREBP1c and FAS expression.
|
29093267 |
2017 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Liver steatosis was reduced by RBEE supplementation of LFD (1% RBEE) and HFD (1 and 5% RBEE) and nuclear peroxisome proliferator-activated receptor-α expression upregulated in the HDF 5% RBEE group.
|
28359358 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
The HC diet also up-regulated the expression of the transcription factor peroxisome proliferator-activated receptor α (PPARα) and its downstream targets involved in fatty acid oxidation, including carnitine palmitoyltransferase-1,2 (CPT-1, CPT-2), liver-fatty acid-binding protein (L-FABP), and acyl-CoA oxidase (ACO).
|
28287130 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recombinant PEDF and PPARα agonist diminished the TNFα-induced hepatic steatosis.
|
28111231 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
|
25605057 |
2015 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis.
|
26323321 |
2015 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
The feed-back loop between miR-17-5p and PPAR-α played a key role in the induction of steatosis and fatty liver development.
|
25896250 |
2015 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Forced FGF21 expression in partial hepatectomized hPPARα(PAC) reduced hepatic steatosis, prevented focal necrosis, and restored liver mass.
|
25991671 |
2015 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical studies have reported that PPARα activation does not improve hepatic steatosis.
|
24926685 |
2014 |